Researchers at Stanford have pioneered a novel approach to tuberculosis (TB) vaccine development by pinpointing a novel T-cell target, a PPE protein epitope, via leading edge T-cell reporter assays and comprehensive peptide library screening.
Stanford researchers have developed EphrinA3 technology to strengthen epithelial barriers by increasing expression of cell-cell adhesion molecules, particularly desmoglein-1 (DSG1) and desmocollin-1 (DSC1).
Diagnosis and sub-typing of inflammatory bowel disease (IBD) subsets, such as Crohn's disease (CD) and ulcerative colitis (UC), often require the use of repeated, invasive, and expensive endoscopy procedures, which are not without risk.
Stanford scientists have developed Plate-C, a high-throughput screening platform that captures genome-wide 3D chromatin architecture as a comprehensive cellular phenotype.
Stanford researchers have developed a technology for the automated separation of arteries and veins in single-phase brain CT angiography (CTA) using graph neural networks, enabling precise collateral scoring and improved stroke prognosis.
Researchers at Stanford in collaboration with researchers at NYU have identified novel epitopes on Lymphocyte activation gene-3 (LAG-3) that regulate T cell activation. Blocking those LAG-3 epitopes has potential as a novel immune checkpoint inhibitor therapy.
Stanford researchers have developed an innovative method for efficiently generating robust lymphatic endothelial cells (iLECs) from human induced pluripotent stem cells (hiPSCs) through transcription factor-based protocols.
Stanford researchers have identified a small set of genes that can be used to diagnose active tuberculosis (TB), distinguish active TB from latent TB or other diseases, and predict progression from latent to active TB months before conventional tests.
Stanford researchers Robert Lowsky and Samuel Strober have developed a strategy for maintaining normal graft function without immune suppression medication. Kidney transplant recipients require lifelong use of immunosuppressants to minimize rejection risk.
Researchers at Stanford have developed methods and compositions to provide inducible production of anti-inflammatory cytokines in mesenchymal stem cells (MSCs).
Stanford scientists have developed a plant-derived zinc protoporphyrin (ZnPP) produced from legume hemoglobin, a breakthrough therapy candidate for treating neonatal jaundice.
Stanford researchers have developed a novel blood-based diagnostic platform that leverages circulating bacteriophage DNA (phage cfDNA) to enable sensitive and highly specific detection of both overt and subclinical bacterial infections, while effectively discriminating them fr
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.